Kristensen Tina Bøgelund, Knutsson Malin L T, Wehland Markus, Laursen Britt Elmedal, Grimm Daniela, Warnke Elisabeth, Magnusson Nils E
Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark.
Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, Magdeburg D-39120, Germany.
Int J Mol Sci. 2014 Dec 11;15(12):23024-41. doi: 10.3390/ijms151223024.
Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. The outcomes of anti-angiogenic therapy have been highly variable in terms of tumor response. New methods are needed to identify patients who will benefit from this regimen. The development of biomarkers and molecular profiling are relevant research areas that may strengthen the ability to focus anti-angiogenic therapy towards suitable patients, thereby increase the cost-effectiveness, currently estimated to be inadequate.
新生血管生成是肿瘤生长和侵袭的关键过程，已成为癌症治疗中一个有前景的靶点。本文综述了三种目前相关的靶向血管内皮生长因子系统的抗血管生成药物：贝伐单抗、雷莫西尤单抗和索拉非尼。在晚期乳腺癌的临床试验中评估了抗血管生成药物在辅助治疗或新辅助治疗中的疗效。迄今为止，总体观察到的临床改善并不令人信服，需要进一步研究来证明抗血管生成药物在乳腺癌治疗中的疗效。抗血管生成治疗的结果在肿瘤反应方面差异很大。需要新的方法来识别将从该治疗方案中获益的患者。生物标志物和分子谱分析的发展是相关的研究领域，可以增强将抗血管生成治疗靶向合适患者的能力，从而提高目前估计不足的成本效益。
